Stoke Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 16, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 16, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. Properties
We currently occupy approximately 38,000 square feet of office and laboratory space in Bedford, Massachusetts, under a lease that expires on December 31, 2026. We believe this facility is suitable and adequate for our current operations. In addition, we have access to expanded office and laboratory space to support our anticipated growth. See “Note 14—Subsequent Events” for more information regarding our expanded space.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.